logo

CRVS

Corvus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CRVS fundamentals

Corvus (CRVS) released its earnings on Nov 4, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.12 (YoY +80.00%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.12
+80.00%
Report date
Nov 4, 2025
CRVS Earnings Call Summary for Q3,2025
  • Financial Stability: $65.7M cash runway supports operations into 2026; R&D expenses up 63% due to soquelitinib trials.
  • Atopic Dermatitis Milestones: Cohort 4 data (Jan 2026) and Phase II trial (Q1 2026) targeting JAK/Dupixent-refractory patients.
  • Oncology Momentum: ASH presentation highlights soquelitinib's >12-month PFS in PTCL; Phase III interim data expected late 2026.
  • Strategic Growth: Exploring asthma, HS, and other I&I indications; new board member to guide commercialization.
EPS
Revenue

Revenue & Expenses

Key Indicators

Corvus (CRVS) key financial stats and ratios, covering profitability, financial health, and leverage.
Corvus (CRVS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Corvus (CRVS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Corvus (CRVS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Corvus (CRVS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Corvus (CRVS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield